Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong
A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal Immunization) The first and only bivalent, single-dose vaccine that fights against both RSV A and RSV B disease through two seasons …